You can buy or sell Endo and other stocks, options, ETFs, and crypto commission-free!
Endo International Plc operates as a pharmaceutical company. It focuses on developing, manufacturing, and distributing of branded and generic pharmaceutical products. Read More The firm operates through the following segments: U.S. Branded-Specialty & Established Pharmaceuticals, U.S. Branded-Sterile Injectables, U.S. Generic Pharmaceuticals and International Pharmaceuticals. The U.S. Branded-Specialty & Established Pharmaceuticals segment offers prescription products to treat and manage conditions in urology, urologic oncology, endocrinology, pain and orthopedics. The U.S. Branded-Sterile Injectables segment consists primarily of branded sterile injectable products such as VASOSTRICT, ADRENALIN and APLISOL, among others, and certain generic sterile injectable products, including ertapenem for injection and ephedrine sulfate injection, among others. The U.S. Generic Pharmaceuticals segment consists of a differentiated product portfolio including solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmics and sprays and includes products in the pain management, urology, central nervous system disorders, immunosuppression, oncology, women's health and cardiovascular disease markets, among others. The International Pharmaceuticals segment includes a variety of pharmaceutical products for the Canadian, Latin American, South African, and world markets. The company was founded in 1997 and is headquartered Dublin, Ireland.
52 Week High
52 Week Low
Endo International PLC
Stocks were indicated to open marginally higher on Wednesday ahead of the FOMC decision on interest rates. With the market having recouped so much ground in 2019, investors need to consider how they want their investments and assets positioned for the rest of 2019 and for the long haul. 24/7 Wall St. reviews dozens of [ ] Endo International PLC Endo International Plc operates as a pharmaceutical company. It focuses on developing, manufacturing, and distributing of branded and generic pharmaceutical produc...
Yahoo FinanceMar 19
Endo Announces Publication Of Collagenase Clostridium Histolyticum (CCH) Phase 2 Data In Dermatologic Surgery
Leading Peer-Reviewed Dermatology Journal Features Phase 2 Data DUBLIN, March 19, 2019 /PRNewswire/ -- Endo International plc (ENDP) today announced the publication of Phase 2 data evaluating collagenase clostridium histolyticum (or "CCH") for the treatment of cellulite in Dermatologic Surgery, the official journal of the American Society for Dermatologic Surgery. CCH is the first and only investigational injectable treatment designed specifically to reduce the appearance of cellulite by disrupting the col...
Expected May 7, Pre-Market